ACADIA PHARMACEUTICALS INC (ACAD) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026after close 35 8-K
Q2 FY2026Tue, Aug 4, 2026after close 35 8-K
Q1 FY2026Wed, May 6, 2026after close 36 8-K
Q4 FY2025Wed, Feb 25, 2026after close 56 8-K
Q3 FY2025Wed, Nov 5, 2025after close 36 8-K
Q2 FY2025Wed, Aug 6, 2025after close 37 8-K
Q1 FY2025Wed, May 7, 2025after close 37 8-K
Q4 FY2024Wed, Feb 26, 2025after close 57 8-K

What they guided beta

Q3 FY2026 "Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results - Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues - Third quarter DAYBUE ® GAAP net sales of $140 million, up 39% year-over-year driven by strong uptake of DAYBUE STIX - Third quarter NUPLAZID ® GAAP net sales of $202 million, up 12% year-over-year on a non-GAAP adjusted basis - Raises 2026 DAYBUE net sales guidance to $505–$520 million; narrows NUPLAZID range and total revenue range - Additional data from Phase 3-enabling RADIANT Phase 2 Study to be pre" exhibit
Q3 FY2026 "As we look ahead to 2027, we anticipate two Phase 2 readouts: ACP-211 in major depressive disorder, and remlifanserin in Lewy body dementia psychosis, for which we are providing timing guidance for the first time." exhibit
Q3 FY2026 "Additional data will be presented at the Clinical Trials on Alzheimer’s Disease conference on November 17, 2026, in Boston." exhibit
Q3 FY2026 "Two Phase 2 readouts anticipated in 2027: ACP-211 in major depressive disorder (MDD) in the second half and, for the first time, guidance for remlifanserin in Lewy body dementia Psychosis (LBDP) in the fourth quarter." exhibit
Q3 FY2026 "Full Year 2026 Financial Guidance (GAAP): Acadia is updating its 2026 guidance:" exhibit
Q2 FY2026 "Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results - Second quarter DAYBUE ® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX - Second quarter NUPLAZID ® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis - Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed NUPLAZID guidance of $760 to $790 million - Topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis anticipated Septembe" exhibit
Q2 FY2026 "We remain confident that both franchises are on track to achieve our long-term ambition of approximately $1.7 billion in annual net sales in 2028." exhibit
Q2 FY2026 "Completed enrollment in the Phase 2 portion of the RADIANT program evaluating remlifanserin in Alzheimer's disease psychosis and initiated Phase 3 screening and enrollment; topline Phase 2 results are expected in September to October 2026." exhibit
Q2 FY2026 "Full Year 2026 Financial Guidance (GAAP): Acadia is updating its 2026 guidance:" exhibit
Q2 FY2026 "results, and the enrollment of the Phase 3 portion of the RADIANT development program, (v) potential approval of DAYBU (trofinetide) in the European Union, (vi) plans for, including timing, development and progress of commercialization or regulatory timelines for our products and our product candidates; (vii) benefits to be derived from and efficacy of our products, including the potential advantages of our products; and (viii) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including our full year 2026 financial guidance and anticipat" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ACAD
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ACAD

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ACAD earnings date badge

HTML

<a href="https://veritasdata.dev/company/ACAD/"><img src="https://veritasdata.dev/embed/ACAD.svg" alt="ACAD earnings date" width="240" height="56"></a>

Markdown

[![ACAD earnings date](https://veritasdata.dev/embed/ACAD.svg)](https://veritasdata.dev/company/ACAD/)

Script

<script async src="https://veritasdata.dev/embed/ACAD.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ACAD"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.